首页 > 最新文献

JAMA Psychiatry最新文献

英文 中文
Mental Health Disorder Trends in Denmark According to Age, Calendar Period, and Birth Cohort. 根据年龄、日历期和出生组群划分的丹麦精神疾病趋势。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-27 DOI: 10.1001/jamapsychiatry.2024.3723
Natalie C Momen, Christoffer Beck, Mette Lise Lousdal, Esben Agerbo, John J McGrath, Carsten B Pedersen, Merete Nordentoft, Oleguer Plana-Ripoll

Importance: Research suggests an increase in mental disorder incidence in recent years, but this trend remains unexplained, and there is a lack of large studies based on a representative sample that investigate mental disorders over the full spectrum.

Objective: To explore sex- and age-specific incidence of any mental disorder and 19 specific disorders according to birth cohort and calendar period.

Design, setting, and participants: This was a population-based cohort study among 5 936 202 individuals aged 1 to 80 years living in Denmark at some point between January 1, 2004, and December 31, 2021. Data were derived from the Danish Civil Registration System and analyzed from February to August 2024.

Exposures: Birth cohort (8 categories from 1924 to 2011) and calendar period (six 3-year categories from 2004 to 2021).

Main outcomes and measures: Incidence rates of mental disorders from 2004 to 2021 by sex and age, according to birth cohort and calendar period, including the first years of the COVID-19 pandemic, using Danish health register data.

Results: The population comprised 2 933 857 female individuals and 3 002 345 male individuals, who were followed up for 83.8 million person-years, with median ages at start and end of follow-up of 30.2 and 46.2 years, respectively. There was an overall mental disorder incidence rate of 55.27 every 10 000 person-years. For diagnoses of any mental disorder, higher incidence rates were observed for more recent birth cohorts and calendar periods in the younger ages. Over older ages, incidence rates did not vary so greatly. An increase was observed in rates of most types of mental disorders, especially among young people, and decreases for other types (eg, substance use disorders). Prominent sex differences were also observed. For example, for schizophrenia, a large increase was seen in incidence rates for female individuals in more recent birth cohorts at younger ages, but no change for male individuals, leading to a higher peak incidence for female individuals than for male individuals in the most recent periods. For personality disorders, a large increase was observed in incidence for female individuals over time and a slight decrease for male individuals.

Conclusions and relevance: This comprehensive investigation of mental disorders incidence in Denmark indicates sex- and age-specific patterns according to birth cohorts and calendar periods. While trends may partly be explained by increases in incidence, several other factors may contribute, such as diagnostic practices, health sector capacity, and risk factors for mental disorders.

重要性:研究表明,近年来精神障碍的发病率有所上升,但这一趋势仍未得到解释,而且缺乏基于代表性样本的大型研究来全面调查精神障碍:目的:根据出生队列和日历期,探讨任何精神障碍和 19 种特定精神障碍的性别和年龄发病率:这是一项以人口为基础的队列研究,研究对象是2004年1月1日至2021年12月31日期间居住在丹麦的5 936 202名1至80岁的人。数据来自丹麦民事登记系统,分析时间为 2024 年 2 月至 8 月:出生队列(1924 年至 2011 年的 8 个类别)和日历期(2004 年至 2021 年的 6 个 3 年类别):主要结果和测量指标:根据丹麦健康登记数据,按出生队列和日历期(包括 COVID-19 大流行的最初几年)划分,2004 年至 2021 年期间按性别和年龄划分的精神障碍发病率:研究对象包括 2 933 857 名女性和 3 002 345 名男性,随访时间为 8 380 万人年,随访开始和结束时的中位年龄分别为 30.2 岁和 46.2 岁。总体精神障碍发病率为每 1 万人年 55.27 例。就任何精神障碍的诊断而言,较新的出生组群和较年轻的日历期间的发病率较高。年龄越大,发病率的差异就越小。大多数类型的精神障碍发病率都有所上升,尤其是在年轻人中,而其他类型的精神障碍(如药物使用障碍)发病率则有所下降。性别差异也很明显。例如,就精神分裂症而言,在最近的出生组群中,年龄较小的女性发病率大幅上升,但男性的发病率却没有变化,这导致在最近的时期,女性的发病率峰值高于男性。在人格障碍方面,随着时间的推移,女性的发病率大幅上升,而男性的发病率则略有下降:这项对丹麦精神障碍发病率的全面调查显示,不同出生组群和不同时期的发病率存在不同的性别和年龄模式。虽然发病率的上升可以部分解释这种趋势,但其他一些因素也可能起作用,如诊断方法、卫生部门的能力以及精神障碍的风险因素。
{"title":"Mental Health Disorder Trends in Denmark According to Age, Calendar Period, and Birth Cohort.","authors":"Natalie C Momen, Christoffer Beck, Mette Lise Lousdal, Esben Agerbo, John J McGrath, Carsten B Pedersen, Merete Nordentoft, Oleguer Plana-Ripoll","doi":"10.1001/jamapsychiatry.2024.3723","DOIUrl":"10.1001/jamapsychiatry.2024.3723","url":null,"abstract":"<p><strong>Importance: </strong>Research suggests an increase in mental disorder incidence in recent years, but this trend remains unexplained, and there is a lack of large studies based on a representative sample that investigate mental disorders over the full spectrum.</p><p><strong>Objective: </strong>To explore sex- and age-specific incidence of any mental disorder and 19 specific disorders according to birth cohort and calendar period.</p><p><strong>Design, setting, and participants: </strong>This was a population-based cohort study among 5 936 202 individuals aged 1 to 80 years living in Denmark at some point between January 1, 2004, and December 31, 2021. Data were derived from the Danish Civil Registration System and analyzed from February to August 2024.</p><p><strong>Exposures: </strong>Birth cohort (8 categories from 1924 to 2011) and calendar period (six 3-year categories from 2004 to 2021).</p><p><strong>Main outcomes and measures: </strong>Incidence rates of mental disorders from 2004 to 2021 by sex and age, according to birth cohort and calendar period, including the first years of the COVID-19 pandemic, using Danish health register data.</p><p><strong>Results: </strong>The population comprised 2 933 857 female individuals and 3 002 345 male individuals, who were followed up for 83.8 million person-years, with median ages at start and end of follow-up of 30.2 and 46.2 years, respectively. There was an overall mental disorder incidence rate of 55.27 every 10 000 person-years. For diagnoses of any mental disorder, higher incidence rates were observed for more recent birth cohorts and calendar periods in the younger ages. Over older ages, incidence rates did not vary so greatly. An increase was observed in rates of most types of mental disorders, especially among young people, and decreases for other types (eg, substance use disorders). Prominent sex differences were also observed. For example, for schizophrenia, a large increase was seen in incidence rates for female individuals in more recent birth cohorts at younger ages, but no change for male individuals, leading to a higher peak incidence for female individuals than for male individuals in the most recent periods. For personality disorders, a large increase was observed in incidence for female individuals over time and a slight decrease for male individuals.</p><p><strong>Conclusions and relevance: </strong>This comprehensive investigation of mental disorders incidence in Denmark indicates sex- and age-specific patterns according to birth cohorts and calendar periods. While trends may partly be explained by increases in incidence, several other factors may contribute, such as diagnostic practices, health sector capacity, and risk factors for mental disorders.</p>","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":""},"PeriodicalIF":22.5,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11603380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Framework for Suicide Risk Screening After Overdose: The Advanced Trauma Life Support (ATLS) Trauma Survey Framework. 用药过量后自杀风险筛查框架:高级创伤生命支持(ATLS)创伤调查框架。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-27 DOI: 10.1001/jamapsychiatry.2024.3833
Matthew Robert Dernbach, Randi N Smith, Joseph E Carpenter
{"title":"A Framework for Suicide Risk Screening After Overdose: The Advanced Trauma Life Support (ATLS) Trauma Survey Framework.","authors":"Matthew Robert Dernbach, Randi N Smith, Joseph E Carpenter","doi":"10.1001/jamapsychiatry.2024.3833","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2024.3833","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":""},"PeriodicalIF":22.5,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics of Adults Treated at Mental Health Treatment Centers in the US, 2022. 2022 年在美国心理健康治疗中心接受治疗的成年人的特征。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-27 DOI: 10.1001/jamapsychiatry.2024.3842
Susan H Busch, Jason Hockenberry, Helen Newton
{"title":"Characteristics of Adults Treated at Mental Health Treatment Centers in the US, 2022.","authors":"Susan H Busch, Jason Hockenberry, Helen Newton","doi":"10.1001/jamapsychiatry.2024.3842","DOIUrl":"10.1001/jamapsychiatry.2024.3842","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":""},"PeriodicalIF":22.5,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11603377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
War Exposure and DNA Methylation in Syrian Refugee Children and Adolescents. 战争暴露与叙利亚难民儿童和青少年的 DNA 甲基化。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-20 DOI: 10.1001/jamapsychiatry.2024.3714
Demelza Smeeth, Simone Ecker, Olga Chervova, Fiona McEwen, Elie Karam, Stephan Beck, Michael Pluess

Importance: Exposure to war is associated with poor mental health outcomes. Adverse and traumatic experiences can lead to long-lasting DNA methylation changes, potentially mediating the link between adversity and mental health. To date, limited studies have investigated the impact of war on DNA methylation in children or adolescents, hampering our understanding of the biological impact of war exposure.

Objective: To identify salivary DNA methylation differences associated with war exposure in refugee children and adolescents.

Design, setting, and participants: This cohort study included Syrian refugee children and adolescents, and their primary caregiver were recruited from tented settlements in Lebanon. Data collection was carried out in 2 waves, 1 year apart, from October 2017 to January 2018 and October 2018 to January 2019. Children and their caregiver were interviewed, and children provided saliva samples for DNA extraction. Data analysis was conducted in 2022, 2023, and 2024.

Exposure: War exposure assessed by interviewing children and their caregiver using the War Events Questionnaire.

Main outcomes and measures: Salivary DNA methylation levels were assayed with the Infinium MethylationEPIC BeadChip (Illumina). Epigenetic aging acceleration was estimated using a set of preexisting epigenetic aging clocks. A literature search was conducted to identify previously reported DNA methylation correlates of childhood trauma.

Results: The study population included 1507 children and adolescents (mean [SD] age, 11.3 [2.4] years; age range, 6-19 years; 793 female [52.6%]). A total of 1449 children provided saliva samples for DNA extraction in year 1, and 872 children provided samples in year 2. Children who reported war events had a number of differentially methylated sites and regions. Enrichment analyses indicated an enrichment of gene sets associated with transmembrane transport, neurotransmission, and intracellular movement in genes that exhibited differential methylation. Sex-stratified analyses found a number of sex-specific DNA methylation differences associated with war exposure. Only 2 of 258 (0.8%) previously reported trauma-associated DNA methylation sites were associated with war exposure (B = -0.004; 95% CI, -0.005 to -0.003; Bonferroni P = .04 and B = -0.005; 95% CI, -0.006 to -0.004; Bonferroni P = .03). Any war exposure or bombardment was nominally associated with decreased epigenetic age using the Horvath multitissue clock (B = -0.39; 95% CI, -0.63 to -0.14; P = .007 and B = -0.42; 95% CI, -0.73 to -0.11; P = .002).

Conclusions and relevance: In this cohort of Syrian refugee children and adolescents, war exposure was associated with a small number of distinct differences in salivary DNA methylation.

重要性:战争暴露与不良的心理健康结果有关。逆境和创伤经历会导致 DNA 甲基化发生长期变化,从而有可能介导逆境与心理健康之间的联系。迄今为止,有关战争对儿童或青少年 DNA 甲基化影响的研究还很有限,这妨碍了我们对战争暴露的生物影响的了解:目的:确定难民儿童和青少年唾液 DNA 甲基化与战争暴露相关的差异:这项队列研究包括从黎巴嫩帐篷定居点招募的叙利亚难民儿童和青少年及其主要照顾者。数据收集分两次进行,每次相隔一年,时间分别为 2017 年 10 月至 2018 年 1 月和 2018 年 10 月至 2019 年 1 月。对儿童及其照顾者进行了访谈,儿童提供了唾液样本以提取 DNA。数据分析于 2022 年、2023 年和 2024 年进行。暴露:通过使用战争事件问卷访问儿童及其照顾者来评估战争暴露:唾液 DNA 甲基化水平通过 Infinium MethylationEPIC BeadChip(Illumina)进行检测。利用一组已有的表观遗传衰老时钟估算表观遗传衰老加速度。研究人员还进行了文献检索,以确定以前报道过的与儿童创伤相关的 DNA 甲基化因素:研究对象包括 1507 名儿童和青少年(平均 [SD] 年龄为 11.3 [2.4] 岁;年龄范围为 6-19 岁;793 名女性 [52.6%])。共有 1449 名儿童在第一年提供了用于提取 DNA 的唾液样本,872 名儿童在第二年提供了样本。报告战争事件的儿童有许多不同的甲基化位点和区域。富集分析表明,与跨膜转运、神经传递和细胞内运动相关的基因集富集在出现差异甲基化的基因中。性别分层分析发现了一些与战争暴露有关的性别特异性 DNA 甲基化差异。之前报道的 258 个创伤相关 DNA 甲基化位点中,只有 2 个(0.8%)与战争暴露有关(B = -0.004;95% CI,-0.005 至 -0.003;Bonferroni P = .04 和 B = -0.005;95% CI,-0.006 至 -0.004;Bonferroni P = .03)。使用Horvath多组织时钟,任何战争暴露或轰炸都与表观遗传年龄的降低有名义上的联系(B = -0.39; 95% CI, -0.63 to -0.14; P = .007 and B = -0.42; 95% CI, -0.73 to -0.11; P = .002):在这批叙利亚难民儿童和青少年中,战争暴露与唾液 DNA 甲基化的少量明显差异有关。
{"title":"War Exposure and DNA Methylation in Syrian Refugee Children and Adolescents.","authors":"Demelza Smeeth, Simone Ecker, Olga Chervova, Fiona McEwen, Elie Karam, Stephan Beck, Michael Pluess","doi":"10.1001/jamapsychiatry.2024.3714","DOIUrl":"10.1001/jamapsychiatry.2024.3714","url":null,"abstract":"<p><strong>Importance: </strong>Exposure to war is associated with poor mental health outcomes. Adverse and traumatic experiences can lead to long-lasting DNA methylation changes, potentially mediating the link between adversity and mental health. To date, limited studies have investigated the impact of war on DNA methylation in children or adolescents, hampering our understanding of the biological impact of war exposure.</p><p><strong>Objective: </strong>To identify salivary DNA methylation differences associated with war exposure in refugee children and adolescents.</p><p><strong>Design, setting, and participants: </strong>This cohort study included Syrian refugee children and adolescents, and their primary caregiver were recruited from tented settlements in Lebanon. Data collection was carried out in 2 waves, 1 year apart, from October 2017 to January 2018 and October 2018 to January 2019. Children and their caregiver were interviewed, and children provided saliva samples for DNA extraction. Data analysis was conducted in 2022, 2023, and 2024.</p><p><strong>Exposure: </strong>War exposure assessed by interviewing children and their caregiver using the War Events Questionnaire.</p><p><strong>Main outcomes and measures: </strong>Salivary DNA methylation levels were assayed with the Infinium MethylationEPIC BeadChip (Illumina). Epigenetic aging acceleration was estimated using a set of preexisting epigenetic aging clocks. A literature search was conducted to identify previously reported DNA methylation correlates of childhood trauma.</p><p><strong>Results: </strong>The study population included 1507 children and adolescents (mean [SD] age, 11.3 [2.4] years; age range, 6-19 years; 793 female [52.6%]). A total of 1449 children provided saliva samples for DNA extraction in year 1, and 872 children provided samples in year 2. Children who reported war events had a number of differentially methylated sites and regions. Enrichment analyses indicated an enrichment of gene sets associated with transmembrane transport, neurotransmission, and intracellular movement in genes that exhibited differential methylation. Sex-stratified analyses found a number of sex-specific DNA methylation differences associated with war exposure. Only 2 of 258 (0.8%) previously reported trauma-associated DNA methylation sites were associated with war exposure (B = -0.004; 95% CI, -0.005 to -0.003; Bonferroni P = .04 and B = -0.005; 95% CI, -0.006 to -0.004; Bonferroni P = .03). Any war exposure or bombardment was nominally associated with decreased epigenetic age using the Horvath multitissue clock (B = -0.39; 95% CI, -0.63 to -0.14; P = .007 and B = -0.42; 95% CI, -0.73 to -0.11; P = .002).</p><p><strong>Conclusions and relevance: </strong>In this cohort of Syrian refugee children and adolescents, war exposure was associated with a small number of distinct differences in salivary DNA methylation.</p>","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":""},"PeriodicalIF":22.5,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11579893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Grief-Specific Cognitive Behavioral Therapy vs Present-Centered Therapy 悲伤认知行为疗法与以现在为中心的疗法
IF 25.8 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-13 DOI: 10.1001/jamapsychiatry.2024.3409
Rita Rosner, Jörn Rau, Anette Kersting, Winfried Rief, Regina Steil, Anna-Maria Rummel, Anna Vogel, Hannah Comtesse
ImportanceProlonged grief disorder (PGD) is included as a new diagnosis in international classification systems. Treatments following a cognitive behavioral model are most effective, but comparisons with active control treatments are scarce.ObjectiveTo examine whether integrative cognitive behavioral therapy for prolonged grief (PG-CBT) is superior to present-centered therapy (PCT).Design, Setting, and ParticipantsThis was a rater-blinded, multicenter, randomized clinical trial (stratified by center and relationship to the deceased) with enrollment from April 2017 to May 2022. The setting included 4 university outpatient clinics in Germany. Eligible participants were aged 18 to 75 years and had PGD based on the Prolonged Grief Disorder 13 (PG-13) interview. Participants were randomized 1:1 to PG-CBT and PCT.InterventionsPG-CBT focused on the exposure to the worst moment of the loss and cognitive restructuring of grief-related cognitions in combination with solution-focused and experiential methods (eg, walk to the grave exercise). PCT was adapted in session length and number to PG-CBT and focused on a supportive relationship and coping with daily problems that may have arisen from the loss or grief symptoms.Main Outcomes and MeasuresAll outcomes were assessed at baseline, after treatment, and 12 months after randomization at follow-up. The primary outcome was a blinded assessment of the PG-13 severity score at follow-up. Secondary outcomes were self-reported depressive, somatic, and overall psychopathological symptoms.ResultsOf 544 treatment-seeking individuals experiencing bereavement, 212 eligible participants (mean [SD] age, 51.8 [13.3] years; 173 female [82%]) with PGD based on the PG-13 interview were randomized to PG-CBT and PCT (n = 106 in each condition). In the intention-to-treat analysis, both treatments yielded high reductions in PGD severity at follow-up (PG-CBT: Cohen <jats:italic>d</jats:italic> = 1.64; 95% CI, 1.31-1.97; PCT: Cohen <jats:italic>d</jats:italic> = 1.38; 95% CI, 1.09-1.66). After treatment, participants receiving PG-CBT demonstrated significantly greater reductions in PGD severity than those receiving PCT (Cohen <jats:italic>d</jats:italic> = 0.31; 95% CI, 0.03-0.57). At follow-up, this effect was only visible on a trend level (Cohen <jats:italic>d</jats:italic> = 0.28; 95% CI, −0.02 to 0.57), whereas participants in the PG-CBT group had significantly less depressive and general psychopathological symptoms. Twenty-three participants (20%) discontinued PG-CBT treatment, and 17 participants (16%) discontinued PCT.Conclusion and RelevanceThis randomized clinical trial demonstrates that PG-CBT was superior to PCT after treatment and at follow-up with regard to comorbid symptoms. Both treatments were shown to be effective and acceptable, showing the potential for dissemination and increasing patient choice.Trial registrationGerman Clinical Trials Register (DRKS) identifier: <jats:ext-link xmlns:xlink="http://www.w3.org/199
重要性长期悲伤障碍(PGD)作为一种新的诊断被纳入国际分类系统。采用认知行为模式的治疗最为有效,但与积极对照治疗的比较却很少。目的研究针对长期悲伤的整合认知行为疗法(PG-CBT)是否优于以现在为中心的疗法(PCT)。设计、环境和参与者这是一项评分者盲法、多中心、随机临床试验(根据中心和与逝者的关系进行分层),入组时间为2017年4月至2022年5月。试验地点包括德国的 4 所大学门诊部。符合条件的参与者年龄在18至75岁之间,并根据 "长期悲伤障碍13"(PG-13)访谈结果患有PGD。干预PG-CBT的重点是让患者面对失去亲人的最糟糕时刻,并结合以解决问题为中心的方法和体验式方法(如步行到坟墓锻炼)对悲伤相关认知进行认知重组。PCT在疗程长度和次数上与PG-CBT相适应,并侧重于支持性关系和应对可能由丧失或悲伤症状引起的日常问题。主要结果和测量所有结果均在基线、治疗后和随机化后12个月的随访中进行评估。主要结果是对随访时的 PG-13 严重程度进行盲法评估。结果在 544 名寻求治疗的丧亲人士中,有 212 名符合条件的参与者(平均 [SD] 年龄 51.8 [13.3] 岁;173 名女性 [82%])根据 PG-13 访谈结果患有 PGD,他们被随机分配到 PG-CBT 和 PCT 治疗中(每种治疗方法的人数均为 106 人)。在意向治疗分析中,两种治疗方法都能在随访时显著降低 PGD 的严重程度(PG-CBT:Cohen d = 1.64;95% CI,1.31-1.97;PCT:Cohen d = 1.38;95% CI,1.09-1.66)。治疗后,接受 PG-CBT 的参与者的 PGD 严重程度明显低于接受 PCT 的参与者(Cohen d = 0.31;95% CI,0.03-0.57)。在随访中,这一效果仅在趋势水平上可见(Cohen d = 0.28;95% CI,-0.02 至 0.57),而 PG-CBT 组参与者的抑郁症状和一般精神病理症状明显减少。23名参与者(20%)中断了PG-CBT治疗,17名参与者(16%)中断了PCT治疗。结论与相关性这项随机临床试验表明,在治疗后和随访期间,就合并症状而言,PG-CBT优于PCT。两种治疗方法均有效且可接受,显示了推广和增加患者选择的潜力:DRKS00012317
{"title":"Grief-Specific Cognitive Behavioral Therapy vs Present-Centered Therapy","authors":"Rita Rosner, Jörn Rau, Anette Kersting, Winfried Rief, Regina Steil, Anna-Maria Rummel, Anna Vogel, Hannah Comtesse","doi":"10.1001/jamapsychiatry.2024.3409","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2024.3409","url":null,"abstract":"ImportanceProlonged grief disorder (PGD) is included as a new diagnosis in international classification systems. Treatments following a cognitive behavioral model are most effective, but comparisons with active control treatments are scarce.ObjectiveTo examine whether integrative cognitive behavioral therapy for prolonged grief (PG-CBT) is superior to present-centered therapy (PCT).Design, Setting, and ParticipantsThis was a rater-blinded, multicenter, randomized clinical trial (stratified by center and relationship to the deceased) with enrollment from April 2017 to May 2022. The setting included 4 university outpatient clinics in Germany. Eligible participants were aged 18 to 75 years and had PGD based on the Prolonged Grief Disorder 13 (PG-13) interview. Participants were randomized 1:1 to PG-CBT and PCT.InterventionsPG-CBT focused on the exposure to the worst moment of the loss and cognitive restructuring of grief-related cognitions in combination with solution-focused and experiential methods (eg, walk to the grave exercise). PCT was adapted in session length and number to PG-CBT and focused on a supportive relationship and coping with daily problems that may have arisen from the loss or grief symptoms.Main Outcomes and MeasuresAll outcomes were assessed at baseline, after treatment, and 12 months after randomization at follow-up. The primary outcome was a blinded assessment of the PG-13 severity score at follow-up. Secondary outcomes were self-reported depressive, somatic, and overall psychopathological symptoms.ResultsOf 544 treatment-seeking individuals experiencing bereavement, 212 eligible participants (mean [SD] age, 51.8 [13.3] years; 173 female [82%]) with PGD based on the PG-13 interview were randomized to PG-CBT and PCT (n = 106 in each condition). In the intention-to-treat analysis, both treatments yielded high reductions in PGD severity at follow-up (PG-CBT: Cohen &lt;jats:italic&gt;d&lt;/jats:italic&gt; = 1.64; 95% CI, 1.31-1.97; PCT: Cohen &lt;jats:italic&gt;d&lt;/jats:italic&gt; = 1.38; 95% CI, 1.09-1.66). After treatment, participants receiving PG-CBT demonstrated significantly greater reductions in PGD severity than those receiving PCT (Cohen &lt;jats:italic&gt;d&lt;/jats:italic&gt; = 0.31; 95% CI, 0.03-0.57). At follow-up, this effect was only visible on a trend level (Cohen &lt;jats:italic&gt;d&lt;/jats:italic&gt; = 0.28; 95% CI, −0.02 to 0.57), whereas participants in the PG-CBT group had significantly less depressive and general psychopathological symptoms. Twenty-three participants (20%) discontinued PG-CBT treatment, and 17 participants (16%) discontinued PCT.Conclusion and RelevanceThis randomized clinical trial demonstrates that PG-CBT was superior to PCT after treatment and at follow-up with regard to comorbid symptoms. Both treatments were shown to be effective and acceptable, showing the potential for dissemination and increasing patient choice.Trial registrationGerman Clinical Trials Register (DRKS) identifier: &lt;jats:ext-link xmlns:xlink=\"http://www.w3.org/199","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"22 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142610551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder 使用致幻剂的急诊就诊与精神分裂症谱系障碍的风险
IF 25.8 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-13 DOI: 10.1001/jamapsychiatry.2024.3532
Daniel T. Myran, Michael Pugliese, Jennifer Xiao, Tyler S. Kaster, M. Ishrat Husain, Kelly K. Anderson, Nicholas Fabiano, Stanley Wong, Jess G. Fiedorowicz, Colleen Webber, Peter Tanuseputro, Marco Solmi
ImportanceInterest in and use of hallucinogens has been increasing rapidly. While a frequently raised concern is that hallucinogens may be associated with an increased risk of psychosis, there are limited data on this association.ObjectivesTo examine whether individuals with an emergency department (ED) visit involving hallucinogen use have an increased risk of developing a schizophrenia spectrum disorder (SSD).Design, Settings, and ParticipantsThis population-based, retrospective cohort study (January 2008 to December 2021) included all individuals aged 14 to 65 years in Ontario, Canada, with no history of psychosis (SSD or substance induced). Data were analyzed from May to August 2024.ExposureAn incident ED visit involving hallucinogen use.Main Outcomes and MeasuresDiagnosis of SSD using a medical record–validated algorithm. Associations between ED visits involving hallucinogens and SSD were estimated using cause-specific adjusted hazard models. Individuals with an incident ED visit involving hallucinogens were compared with members of the general population (primary analysis) or individuals with ED visits involving alcohol or cannabis (secondary analysis).ResultsThe study included 9 244 292 individuals (mean [SD] age, 40.4 [14.7] years; 50.2% female) without a history of psychosis, with a median follow-up of 5.1 years (IQR, 2.3-8.6 years); 5217 (0.1%) had an incident ED visit involving hallucinogen use. Annual rates of incident ED visits involving hallucinogens were stable between 2008 and 2012 and then increased by 86.4% between 2013 and 2021 (3.4 vs 6.4 per 100 000 individuals). Individuals with ED visits involving hallucinogens had a greater risk of being diagnosed with an SSD within 3 years compared with the general population (age- and sex-adjusted hazard ratio [HR], 21.32 [95% CI, 18.58-24.47]; absolute proportion with SSD at 3 years, 208 of 5217 with hallucinogen use [3.99%] vs 13 639 of 9 239 075 in the general population [0.15%]). After adjustment for comorbid substance use and mental health conditions, individuals with hallucinogen ED visits had a greater risk of SSD compared with the general population (HR, 3.53; 95% CI, 3.05-4.09). Emergency department visits involving hallucinogens were associated with an increased risk of SSD within 3 years compared with ED visits involving alcohol (HR, 4.66; 95% CI, 3.82-5.68) and cannabis (HR, 1.47; 95% CI, 1.21-1.80) in the fully adjusted model.Conclusions and RelevanceIn this cohort study, individuals with an ED visit involving hallucinogen use had a greater risk of developing an SSD compared with both the general population and with individuals with ED visits for other types of substances. These findings have important clinical and policy implications given the increasing use of hallucinogens and associated ED visits.
重要性人们对致幻剂的兴趣和使用在迅速增加。这项基于人群的回顾性队列研究(2008 年 1 月至 2021 年 12 月)纳入了加拿大安大略省所有年龄在 14 岁至 65 岁之间、无精神病史(SSD 或药物诱发)的人。主要结果和测量指标使用经过医疗记录验证的算法诊断出 SSD。使用病因特异性调整危险模型估算涉及致幻剂的急诊就诊与 SSD 之间的关系。研究纳入了 9 244 292 人(平均 [SD] 年龄为 40.4 [14.7] 岁;50.2% 为女性),均无精神病史,中位随访时间为 5.1 年(IQR,2.3-8.6 年);5217 人(0.1%)曾因使用致幻剂而在急诊就诊。2008年至2012年期间,使用致幻剂的急诊室就诊率保持稳定,2013年至2021年期间增加了86.4%(每10万人中有3.4人就诊,每10万人中有6.4人就诊)。与普通人群相比,使用致幻剂的 ED 患者在 3 年内被诊断为 SSD 的风险更高(经年龄和性别调整后的危险比 [HR],21.32 [95% CI,18.58-24.47];3 年后患 SSD 的绝对比例为:使用致幻剂的 5217 人中有 208 人 [3.99%] ,而普通人群为 9 239 075 人中有 13 639 人 [0.15%])。在对合并药物使用和精神健康状况进行调整后,与普通人群相比,使用致幻剂的急诊就诊者患 SSD 的风险更高(HR,3.53;95% CI,3.05-4.09)。在完全调整模型中,与使用酒精(HR,4.66;95% CI,3.82-5.68)和大麻(HR,1.47;95% CI,1.21-1.80)的急诊就诊相比,使用致幻剂的急诊就诊者在 3 年内罹患 SSD 的风险更高。在这项队列研究中,与普通人群和使用其他类型药物的急诊就诊者相比,使用致幻剂的急诊就诊者罹患 SSD 的风险更高。鉴于致幻剂的使用和相关的急诊就诊日益增多,这些发现对临床和政策具有重要意义。
{"title":"Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder","authors":"Daniel T. Myran, Michael Pugliese, Jennifer Xiao, Tyler S. Kaster, M. Ishrat Husain, Kelly K. Anderson, Nicholas Fabiano, Stanley Wong, Jess G. Fiedorowicz, Colleen Webber, Peter Tanuseputro, Marco Solmi","doi":"10.1001/jamapsychiatry.2024.3532","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2024.3532","url":null,"abstract":"ImportanceInterest in and use of hallucinogens has been increasing rapidly. While a frequently raised concern is that hallucinogens may be associated with an increased risk of psychosis, there are limited data on this association.ObjectivesTo examine whether individuals with an emergency department (ED) visit involving hallucinogen use have an increased risk of developing a schizophrenia spectrum disorder (SSD).Design, Settings, and ParticipantsThis population-based, retrospective cohort study (January 2008 to December 2021) included all individuals aged 14 to 65 years in Ontario, Canada, with no history of psychosis (SSD or substance induced). Data were analyzed from May to August 2024.ExposureAn incident ED visit involving hallucinogen use.Main Outcomes and MeasuresDiagnosis of SSD using a medical record–validated algorithm. Associations between ED visits involving hallucinogens and SSD were estimated using cause-specific adjusted hazard models. Individuals with an incident ED visit involving hallucinogens were compared with members of the general population (primary analysis) or individuals with ED visits involving alcohol or cannabis (secondary analysis).ResultsThe study included 9 244 292 individuals (mean [SD] age, 40.4 [14.7] years; 50.2% female) without a history of psychosis, with a median follow-up of 5.1 years (IQR, 2.3-8.6 years); 5217 (0.1%) had an incident ED visit involving hallucinogen use. Annual rates of incident ED visits involving hallucinogens were stable between 2008 and 2012 and then increased by 86.4% between 2013 and 2021 (3.4 vs 6.4 per 100 000 individuals). Individuals with ED visits involving hallucinogens had a greater risk of being diagnosed with an SSD within 3 years compared with the general population (age- and sex-adjusted hazard ratio [HR], 21.32 [95% CI, 18.58-24.47]; absolute proportion with SSD at 3 years, 208 of 5217 with hallucinogen use [3.99%] vs 13 639 of 9 239 075 in the general population [0.15%]). After adjustment for comorbid substance use and mental health conditions, individuals with hallucinogen ED visits had a greater risk of SSD compared with the general population (HR, 3.53; 95% CI, 3.05-4.09). Emergency department visits involving hallucinogens were associated with an increased risk of SSD within 3 years compared with ED visits involving alcohol (HR, 4.66; 95% CI, 3.82-5.68) and cannabis (HR, 1.47; 95% CI, 1.21-1.80) in the fully adjusted model.Conclusions and RelevanceIn this cohort study, individuals with an ED visit involving hallucinogen use had a greater risk of developing an SSD compared with both the general population and with individuals with ED visits for other types of substances. These findings have important clinical and policy implications given the increasing use of hallucinogens and associated ED visits.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"70 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142610548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder 将塞马鲁肽和利拉鲁肽重新用于酒精使用障碍的治疗
IF 25.8 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-13 DOI: 10.1001/jamapsychiatry.2024.3599
Markku Lähteenvuo, Jari Tiihonen, Anssi Solismaa, Antti Tanskanen, Ellenor Mittendorfer-Rutz, Heidi Taipale
ImportancePreliminary studies suggest that glucagon-like peptide-1 receptor (GLP-1) agonists, used to treat type 2 diabetes and obesity, may decrease alcohol consumption.ObjectiveTo test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.Design, Setting, and ParticipantsThis cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023. The population-based cohort was identified from registers of inpatient care, specialized outpatient care, sickness absence, and disability pension. Participants were all residents aged 16 to 64 years who had a diagnosis of AUD.ExposuresThe primary exposure was use of individual GLP-1 agonists (compared with nonuse of GLP-1 agonists), and the secondary exposure was medications with indication for AUD.Main Outcomes and MeasuresThe primary outcome was AUD hospitalization analyzed in a Cox regression within-individual model. Secondary outcomes were any substance use disorder (SUD)–related hospitalization, somatic hospitalization, and suicide attempt.ResultsThe cohort included 227 866 individuals with AUD; 144 714 (63.5%) were male and 83 154 (36.5%) were female, with a mean (SD) age of 40.0 (15.7) years. Median (IQR) follow-up time was 8.8 (4.0-13.3) years. A total of 133 210 individuals (58.5%) experienced AUD hospitalization. Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83; any SUD: aHR, 0.68; 95% CI, 0.54-0.85) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92; any SUD: aHR, 0.78; 95% CI, 0.64-0.97) of both AUD and SUD hospitalization. Use of any AUD medication was associated with a modestly decreased risk (aHR, 0.98; 95% CI, 0.96-1.00). Semaglutide (aHR, 0.78; 95% CI, 0.68-0.90) and liraglutide (aHR, 0.79; 95% CI, 0.69-0.91) use were also associated with decreased risk of somatic hospitalizations but not associated with suicide attempts (semaglutide: aHR, 0.55; 95% CI, 0.23-1.30; liraglutide: aHR, 1.08; 95% CI, 0.55-2.15).Conclusions and RelevanceAmong patients with AUD and comorbid obesity/type 2 diabetes, the use of semaglutide and liraglutide were associated with a substantially decreased risk of hospitalization due to AUD. This risk was lower than that of officially approved AUD medications. Semaglutide and liraglutide may be effective in the treatment of AUD, and clinical trials are urgently needed to confirm these findings.
重要性初步研究表明,用于治疗 2 型糖尿病和肥胖症的胰高血糖素样肽-1 受体 (GLP-1) 激动剂可能会降低饮酒量。目的测试与未使用 GLP-1 激动剂期间相比,同一患者在使用 GLP-1 激动剂期间因饮酒紊乱 (AUD) 而住院的风险是否会降低。研究人员从住院病人、专科门诊病人、因病缺勤病人和残疾抚恤金登记册中确定了人群队列。主要暴露是使用单个 GLP-1 激动剂(与不使用 GLP-1 激动剂进行比较),次要暴露是具有 AUD 适应症的药物。结果队列中包括 227 866 名 AUD 患者,其中男性 144 714 人(63.5%),女性 83 154 人(36.5%),平均(标清)年龄为 40.0(15.7)岁。随访时间中位数(IQR)为 8.8(4.0-13.3)年。共有 133 210 人(58.5%)经历过 AUD 住院治疗。塞马鲁肽(4321 名使用者)与最低风险相关(AUD:调整后危险比 [aHR],0.64;95% CI,0.50-0.83;任何 SUD:aHR,0.68;95% CI,0.54-0.85),而使用利拉鲁肽(4321 名使用者)与最低风险相关。85)和使用利拉鲁肽(2509 名使用者)的 AUD 和 SUD 住院风险第二低(AUD:aHR,0.72;95% CI,0.57-0.92;任何 SUD:aHR,0.78;95% CI,0.64-0.97)。使用任何 AUD 药物都会导致风险略有降低(aHR,0.98;95% CI,0.96-1.00)。使用塞马鲁肽(aHR,0.78;95% CI,0.68-0.90)和利拉鲁肽(aHR,0.79;95% CI,0.69-0.91)也与躯体住院风险降低有关,但与自杀未遂无关(塞马鲁肽:aHR,0.55;95% CI,0.23-1.结论和相关性在患有 AUD 和合并肥胖/2 型糖尿病的患者中,使用塞马鲁肽和利拉鲁肽与 AUD 导致的住院风险大幅降低有关。这一风险低于官方批准的抗焦虑和抑郁药物。塞马鲁肽和利拉鲁肽可能对治疗AUD有效,目前急需进行临床试验来证实这些发现。
{"title":"Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder","authors":"Markku Lähteenvuo, Jari Tiihonen, Anssi Solismaa, Antti Tanskanen, Ellenor Mittendorfer-Rutz, Heidi Taipale","doi":"10.1001/jamapsychiatry.2024.3599","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2024.3599","url":null,"abstract":"ImportancePreliminary studies suggest that glucagon-like peptide-1 receptor (GLP-1) agonists, used to treat type 2 diabetes and obesity, may decrease alcohol consumption.ObjectiveTo test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.Design, Setting, and ParticipantsThis cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023. The population-based cohort was identified from registers of inpatient care, specialized outpatient care, sickness absence, and disability pension. Participants were all residents aged 16 to 64 years who had a diagnosis of AUD.ExposuresThe primary exposure was use of individual GLP-1 agonists (compared with nonuse of GLP-1 agonists), and the secondary exposure was medications with indication for AUD.Main Outcomes and MeasuresThe primary outcome was AUD hospitalization analyzed in a Cox regression within-individual model. Secondary outcomes were any substance use disorder (SUD)–related hospitalization, somatic hospitalization, and suicide attempt.ResultsThe cohort included 227 866 individuals with AUD; 144 714 (63.5%) were male and 83 154 (36.5%) were female, with a mean (SD) age of 40.0 (15.7) years. Median (IQR) follow-up time was 8.8 (4.0-13.3) years. A total of 133 210 individuals (58.5%) experienced AUD hospitalization. Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83; any SUD: aHR, 0.68; 95% CI, 0.54-0.85) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92; any SUD: aHR, 0.78; 95% CI, 0.64-0.97) of both AUD and SUD hospitalization. Use of any AUD medication was associated with a modestly decreased risk (aHR, 0.98; 95% CI, 0.96-1.00). Semaglutide (aHR, 0.78; 95% CI, 0.68-0.90) and liraglutide (aHR, 0.79; 95% CI, 0.69-0.91) use were also associated with decreased risk of somatic hospitalizations but not associated with suicide attempts (semaglutide: aHR, 0.55; 95% CI, 0.23-1.30; liraglutide: aHR, 1.08; 95% CI, 0.55-2.15).Conclusions and RelevanceAmong patients with AUD and comorbid obesity/type 2 diabetes, the use of semaglutide and liraglutide were associated with a substantially decreased risk of hospitalization due to AUD. This risk was lower than that of officially approved AUD medications. Semaglutide and liraglutide may be effective in the treatment of AUD, and clinical trials are urgently needed to confirm these findings.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"11 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142610134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synaptic Density in Early Stages of Psychosis and Clinical High Risk 精神病早期和临床高危人群的突触密度
IF 25.8 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-13 DOI: 10.1001/jamapsychiatry.2024.3608
M. Belen Blasco, Kankana Nisha Aji, Christian Ramos-Jiménez, Ilana Ruth Leppert, Christine Lucas Tardif, Johan Cohen, Pablo M. Rusjan, Romina Mizrahi
ImportanceSynaptic dysfunction is involved in schizophrenia pathophysiology. However, whether in vivo synaptic density is reduced in early stages of psychosis, including its high-risk states, remains unclear.ObjectiveTo investigate whether synaptic density (synaptic vesicle glycoprotein 2A [SV2A] binding potential) is reduced in first-episode psychosis (FEP) and in clinical high risk (CHR) and investigate the effect of cannabis use on synaptic density and examine its relationship with psychotic symptoms and gray matter microstructure across groups.Design, Setting, and ParticipantsThis cross-sectional study was performed in a tertiary care psychiatric hospital from July 2021 to October 2023. Participants were patients with antipsychotic-free or minimally exposed FEP or CHR and healthy controls with a clean urine drug screen (except cannabis).Main Outcomes and MeasuresSynaptic density was quantified with dynamic 90-minute [<jats:sup>18</jats:sup>F]SynVesT-1 positron emission tomography (PET) scans across prioritized brain regions of interest (ROIs) delineated in individual magnetic resonance images (MRIs). Cannabis use was confirmed with urine drug screens. Gray matter microstructure was assessed using diffusion-weighted MRI to estimate neurite density.ResultsA total of 49 participants were included, including 16 patients with FEP (mean [SD] age, 26.1 [4.6] years; 9 males and 7 females), 17 patients at CHR (mean [SD] age, 21.2 [3.5] years; 8 males and 9 females), and 16 healthy controls (mean [SD] age, 23.4 [3.6] years; 7 males and 9 females). Synaptic density was significantly different between groups (<jats:italic>F</jats:italic><jats:sub>2,273</jats:sub> = 4.02, <jats:italic>P</jats:italic> = .02, Cohen <jats:italic>F</jats:italic> = 0.17; ROI: <jats:italic>F</jats:italic><jats:sub>5,273</jats:sub> = 360.18, <jats:italic>P</jats:italic> &amp;lt; .01, Cohen <jats:italic>F</jats:italic> = 2.55) with a group × ROI interaction (<jats:italic>F</jats:italic><jats:sub>10,273</jats:sub> = 2.67, <jats:italic>P</jats:italic> &amp;lt; .01, Cohen <jats:italic>F</jats:italic> = 0.32). Synaptic density was lower in cannabis users (<jats:italic>F</jats:italic><jats:sub>1,272</jats:sub> = 5.31, <jats:italic>P</jats:italic> = .02, Cohen <jats:italic>F</jats:italic> = 0.14). Lower synaptic density across groups was associated with more negative symptoms (Positive and Negative Syndrome Scale negative scores: <jats:italic>F</jats:italic><jats:sub>1,81</jats:sub> = 4.31, <jats:italic>P</jats:italic> = .04, Cohen <jats:italic>F</jats:italic> = 0.23; Scale of Psychosis-Risk Symptoms negative scores: <jats:italic>F</jats:italic><jats:sub>1,90</jats:sub> = 4.12, <jats:italic>P</jats:italic> = .04, Cohen <jats:italic>F</jats:italic> = 0.21). SV2A binding potential was significantly associated with neurite density index (<jats:italic>F</jats:italic><jats:sub>1,138</jats:sub> = 6.76, <jats:italic>P</jats:italic> = .01, Cohen <jats:italic>F</jats:italic> = 0.22).Con
重要性突触功能障碍与精神分裂症的病理生理学有关。目的 研究首发精神病(FEP)和临床高危精神病(CHR)患者的突触密度(突触小泡糖蛋白 2A [SV2A] 结合电位)是否降低,调查使用大麻对突触密度的影响,并研究其与各组精神病症状和灰质微结构的关系。这项横断面研究于 2021 年 7 月至 2023 年 10 月在一家三级精神病医院进行。主要结果和测量突触密度采用 90 分钟动态[18F]SynVesT-1 正电子发射断层扫描(PET)进行量化,扫描范围为单个磁共振图像(MRI)中划定的优先大脑感兴趣区(ROI)。通过尿液药物筛查确认是否吸食大麻。结果 共纳入 49 名参与者,包括 16 名 FEP 患者(平均 [SD] 年龄 26.1 [4.6] 岁;男性 9 名,女性 7 名)、17 名 CHR 患者(平均 [SD] 年龄 21.2 [3.5] 岁;男性 8 名,女性 9 名)和 16 名健康对照组(平均 [SD] 年龄 23.4 [3.6] 岁;男性 7 名,女性 9 名)。突触密度在组间存在明显差异(F2,273 = 4.02,P = .02,Cohen F = 0.17;ROI:F5,273 = 360.18,P &p;amp;lt; .01,Cohen F = 2.55),组与 ROI 之间存在交互作用(F10,273 = 2.67,P &p;amp;lt; .01,Cohen F = 0.32)。大麻使用者的突触密度较低(F1,272 = 5.31,P = .02,Cohen F = 0.14)。各组较低的突触密度与较多的负面症状有关(正负综合征量表负分:F1,81 = 4.31,Cohen F = 0.32):F1,81 = 4.31,P = .04,Cohen F = 0.23;Scale of Psychosis-Risk Symptoms negative scores:F1,90 = 4.12,P = .04,Cohen F = 0.21)。SV2A 结合电位与神经元密度指数显著相关(F1,138 = 6.76,P = .01,Cohen F = 0.22)。SV2A 对精神病和慢性精神障碍患者的阴性症状的影响值得进一步研究。未来的研究应纵向调查使用大麻对 CHR 中突触密度的影响。
{"title":"Synaptic Density in Early Stages of Psychosis and Clinical High Risk","authors":"M. Belen Blasco, Kankana Nisha Aji, Christian Ramos-Jiménez, Ilana Ruth Leppert, Christine Lucas Tardif, Johan Cohen, Pablo M. Rusjan, Romina Mizrahi","doi":"10.1001/jamapsychiatry.2024.3608","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2024.3608","url":null,"abstract":"ImportanceSynaptic dysfunction is involved in schizophrenia pathophysiology. However, whether in vivo synaptic density is reduced in early stages of psychosis, including its high-risk states, remains unclear.ObjectiveTo investigate whether synaptic density (synaptic vesicle glycoprotein 2A [SV2A] binding potential) is reduced in first-episode psychosis (FEP) and in clinical high risk (CHR) and investigate the effect of cannabis use on synaptic density and examine its relationship with psychotic symptoms and gray matter microstructure across groups.Design, Setting, and ParticipantsThis cross-sectional study was performed in a tertiary care psychiatric hospital from July 2021 to October 2023. Participants were patients with antipsychotic-free or minimally exposed FEP or CHR and healthy controls with a clean urine drug screen (except cannabis).Main Outcomes and MeasuresSynaptic density was quantified with dynamic 90-minute [&lt;jats:sup&gt;18&lt;/jats:sup&gt;F]SynVesT-1 positron emission tomography (PET) scans across prioritized brain regions of interest (ROIs) delineated in individual magnetic resonance images (MRIs). Cannabis use was confirmed with urine drug screens. Gray matter microstructure was assessed using diffusion-weighted MRI to estimate neurite density.ResultsA total of 49 participants were included, including 16 patients with FEP (mean [SD] age, 26.1 [4.6] years; 9 males and 7 females), 17 patients at CHR (mean [SD] age, 21.2 [3.5] years; 8 males and 9 females), and 16 healthy controls (mean [SD] age, 23.4 [3.6] years; 7 males and 9 females). Synaptic density was significantly different between groups (&lt;jats:italic&gt;F&lt;/jats:italic&gt;&lt;jats:sub&gt;2,273&lt;/jats:sub&gt; = 4.02, &lt;jats:italic&gt;P&lt;/jats:italic&gt; = .02, Cohen &lt;jats:italic&gt;F&lt;/jats:italic&gt; = 0.17; ROI: &lt;jats:italic&gt;F&lt;/jats:italic&gt;&lt;jats:sub&gt;5,273&lt;/jats:sub&gt; = 360.18, &lt;jats:italic&gt;P&lt;/jats:italic&gt; &amp;amp;lt; .01, Cohen &lt;jats:italic&gt;F&lt;/jats:italic&gt; = 2.55) with a group × ROI interaction (&lt;jats:italic&gt;F&lt;/jats:italic&gt;&lt;jats:sub&gt;10,273&lt;/jats:sub&gt; = 2.67, &lt;jats:italic&gt;P&lt;/jats:italic&gt; &amp;amp;lt; .01, Cohen &lt;jats:italic&gt;F&lt;/jats:italic&gt; = 0.32). Synaptic density was lower in cannabis users (&lt;jats:italic&gt;F&lt;/jats:italic&gt;&lt;jats:sub&gt;1,272&lt;/jats:sub&gt; = 5.31, &lt;jats:italic&gt;P&lt;/jats:italic&gt; = .02, Cohen &lt;jats:italic&gt;F&lt;/jats:italic&gt; = 0.14). Lower synaptic density across groups was associated with more negative symptoms (Positive and Negative Syndrome Scale negative scores: &lt;jats:italic&gt;F&lt;/jats:italic&gt;&lt;jats:sub&gt;1,81&lt;/jats:sub&gt; = 4.31, &lt;jats:italic&gt;P&lt;/jats:italic&gt; = .04, Cohen &lt;jats:italic&gt;F&lt;/jats:italic&gt; = 0.23; Scale of Psychosis-Risk Symptoms negative scores: &lt;jats:italic&gt;F&lt;/jats:italic&gt;&lt;jats:sub&gt;1,90&lt;/jats:sub&gt; = 4.12, &lt;jats:italic&gt;P&lt;/jats:italic&gt; = .04, Cohen &lt;jats:italic&gt;F&lt;/jats:italic&gt; = 0.21). SV2A binding potential was significantly associated with neurite density index (&lt;jats:italic&gt;F&lt;/jats:italic&gt;&lt;jats:sub&gt;1,138&lt;/jats:sub&gt; = 6.76, &lt;jats:italic&gt;P&lt;/jats:italic&gt; = .01, Cohen &lt;jats:italic&gt;F&lt;/jats:italic&gt; = 0.22).Con","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"44 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142610141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychosis Spectrum Symptoms Before and After Adolescent Cannabis Use Initiation. 青少年开始吸食大麻前后的精神病谱系症状。
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-06 DOI: 10.1001/jamapsychiatry.2024.3525
K Juston Osborne, Deanna M Barch, Joshua J Jackson, Nicole R Karcher

Importance: Adolescent cannabis use has been consistently posited to contribute to the onset and progression of psychosis. However, alternative causal models may account for observed associations between cannabis use and psychosis risk, including shared vulnerability for both cannabis use and psychosis or efforts to self-medicate distress from psychosis spectrum symptomology.

Objective: To test 3 hypotheses that may explain cannabis-psychosis risk associations by modeling psychosis spectrum symptom trajectories prior to and after cannabis initiation across adolescent development (approximately 10-15 years of age).

Design, setting, and participants: This cohort study used data from 5 waves across 4 years of follow-up from the Adolescent Brain Cognitive Development (ABCD) Study. The ABCD study is an ongoing large-scale, longitudinal study of brain development and mental and physical health of children in the US launched in June 2016. Data are collected from 21 research sites. The study included data from 11 868 adolescents aged 9 to 10 years at baseline. Three participants were excluded from the present analysis owing to missing data. Data analysis was performed from September 2023 to July 2024.

Main outcomes and measures: Discontinuous growth curve modeling was used to assess trajectories of psychosis spectrum symptoms before and after cannabis initiation. Control variables considered for this investigation were age, sex, internalizing and externalizing symptoms, socioeconomic status, parental mental health, and other substance use.

Results: Among the 11 858 participants at wave 1, the mean (SD) age was 9.5 (0.5) years; 6182 (52%) participants were male. Consistent with a shared vulnerability hypothesis, adolescents who used cannabis at any point during the study period reported a greater number of psychosis spectrum symptoms (B, 0.86; 95% CI, 0.68-1.04) and more distress (B, 1.17; 95% CI, 0.96-1.39) from psychosis spectrum symptoms relative to those who never used cannabis. Additionally, consistent with a self-medication hypothesis, the number of psychosis spectrum symptoms (B, 0.16; 95% CI, 0.12-0.20) and distress (B, 0.23; 95% CI, 0.21-0.26) from psychosis spectrum symptoms increased in the time leading up to cannabis initiation. We observed mixed evidence for an increase in psychosis symptoms after cannabis initiation (ie, contributing risk hypothesis).

Conclusion and relevance: The findings underscore the importance of accounting for shared vulnerability and self-medication effects when modeling cannabis-psychosis risk associations.

重要性:青少年吸食大麻一直被认为会导致精神病的发生和发展。然而,其他的因果模型也可能解释所观察到的吸食大麻与精神病风险之间的关联,包括吸食大麻与精神病的共同易感性或自我治疗精神病症状的努力:通过对整个青少年成长过程(约 10-15 岁)中开始吸食大麻前后的精神病谱系症状轨迹建模,检验可能解释大麻与精神病风险关联的 3 个假设:这项队列研究使用了青少年大脑认知发展(ABCD)研究 4 年间 5 次随访的数据。ABCD研究是一项正在进行中的大规模纵向研究,研究对象是美国儿童的大脑发育和身心健康,于2016年6月启动。数据从 21 个研究点收集。该研究包括11 868名9至10岁青少年的基线数据。由于数据缺失,本分析排除了三名参与者。数据分析时间为2023年9月至2024年7月:采用非连续增长曲线模型评估开始吸食大麻前后的精神病谱系症状轨迹。这项调查考虑的控制变量包括年龄、性别、内化和外化症状、社会经济状况、父母精神健康状况以及其他药物使用情况:在第一轮调查的 11 858 名参与者中,平均(标清)年龄为 9.5(0.5)岁;6182 人(52%)为男性。与共同易感性假设一致的是,与从未使用过大麻的青少年相比,在研究期间任何时候使用过大麻的青少年报告了更多的精神病谱系症状(B,0.86;95% CI,0.68-1.04)和更多的精神病谱系症状带来的困扰(B,1.17;95% CI,0.96-1.39)。此外,与自我药疗假说一致的是,在开始吸食大麻之前的一段时间内,精神病谱系症状的数量(B,0.16;95% CI,0.12-0.20)和精神病谱系症状造成的痛苦(B,0.23;95% CI,0.21-0.26)均有所增加。我们观察到混合证据表明,开始吸食大麻后精神病症状会增加(即促成风险假设):研究结果强调了在建立大麻与精神病风险关联模型时考虑共同易感性和自我医疗效应的重要性。
{"title":"Psychosis Spectrum Symptoms Before and After Adolescent Cannabis Use Initiation.","authors":"K Juston Osborne, Deanna M Barch, Joshua J Jackson, Nicole R Karcher","doi":"10.1001/jamapsychiatry.2024.3525","DOIUrl":"10.1001/jamapsychiatry.2024.3525","url":null,"abstract":"<p><strong>Importance: </strong>Adolescent cannabis use has been consistently posited to contribute to the onset and progression of psychosis. However, alternative causal models may account for observed associations between cannabis use and psychosis risk, including shared vulnerability for both cannabis use and psychosis or efforts to self-medicate distress from psychosis spectrum symptomology.</p><p><strong>Objective: </strong>To test 3 hypotheses that may explain cannabis-psychosis risk associations by modeling psychosis spectrum symptom trajectories prior to and after cannabis initiation across adolescent development (approximately 10-15 years of age).</p><p><strong>Design, setting, and participants: </strong>This cohort study used data from 5 waves across 4 years of follow-up from the Adolescent Brain Cognitive Development (ABCD) Study. The ABCD study is an ongoing large-scale, longitudinal study of brain development and mental and physical health of children in the US launched in June 2016. Data are collected from 21 research sites. The study included data from 11 868 adolescents aged 9 to 10 years at baseline. Three participants were excluded from the present analysis owing to missing data. Data analysis was performed from September 2023 to July 2024.</p><p><strong>Main outcomes and measures: </strong>Discontinuous growth curve modeling was used to assess trajectories of psychosis spectrum symptoms before and after cannabis initiation. Control variables considered for this investigation were age, sex, internalizing and externalizing symptoms, socioeconomic status, parental mental health, and other substance use.</p><p><strong>Results: </strong>Among the 11 858 participants at wave 1, the mean (SD) age was 9.5 (0.5) years; 6182 (52%) participants were male. Consistent with a shared vulnerability hypothesis, adolescents who used cannabis at any point during the study period reported a greater number of psychosis spectrum symptoms (B, 0.86; 95% CI, 0.68-1.04) and more distress (B, 1.17; 95% CI, 0.96-1.39) from psychosis spectrum symptoms relative to those who never used cannabis. Additionally, consistent with a self-medication hypothesis, the number of psychosis spectrum symptoms (B, 0.16; 95% CI, 0.12-0.20) and distress (B, 0.23; 95% CI, 0.21-0.26) from psychosis spectrum symptoms increased in the time leading up to cannabis initiation. We observed mixed evidence for an increase in psychosis symptoms after cannabis initiation (ie, contributing risk hypothesis).</p><p><strong>Conclusion and relevance: </strong>The findings underscore the importance of accounting for shared vulnerability and self-medication effects when modeling cannabis-psychosis risk associations.</p>","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":""},"PeriodicalIF":22.5,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11541740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflammatory Biomarkers and Risk of Psychiatric Disorders. 炎症生物标志物与精神疾病风险
IF 22.5 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-11-01 DOI: 10.1001/jamapsychiatry.2024.2185
Yu Zeng, Charilaos Chourpiliadis, Niklas Hammar, Christina Seitz, Unnur A Valdimarsdóttir, Fang Fang, Huan Song, Dang Wei

Importance: Individuals with psychiatric disorders have been reported to have elevated levels of inflammatory biomarkers, and prospective evidence is limited regarding the association between inflammatory biomarkers and subsequent psychiatric disorders risk.

Objective: To assess the associations between inflammation biomarkers and subsequent psychiatric disorders risk.

Design, setting, and participants: This was a prospective cohort study including individuals from the Swedish Apolipoprotein Mortality Risk (AMORIS) cohort, with no prior psychiatric diagnoses and having a measurement of at least 1 inflammatory biomarker. Data from the UK Biobank were used for validation. Longitudinal trajectories of studied biomarkers were visualized before diagnosis of psychiatric disorders in the AMORIS cohort via a nested case-control study. In addition, genetic correlation and mendelian randomization (MR) analyses were conducted to determine the genetic overlap and causality of the studied associations using publicly available GWAS summary statistics.

Exposures: Inflammatory biomarkers, eg, leukocytes, haptoglobin, immunoglobulin G (IgG), C-reactive protein (CRP), platelets, or albumin.

Main outcomes and measures: Any psychiatric disorder or specific psychiatric disorder (ie, depression, anxiety, and stress-related disorders) was identified through the International Statistical Classification of Diseases, Eighth, Ninth, and Tenth Revision codes.

Results: Among the 585 279 individuals (mean [SD] age, 45.5 [14.9] years; 306 784 male [52.4%]) in the AMORIS cohort, individuals with a higher than median level of leukocytes (hazard ratio [HR], 1.11; 95% CI, 1.09-1.14), haptoglobin (HR, 1.13; 95% CI, 1.12-1.14), or CRP (HR, 1.02; 95% CI, 1.00-1.04) had an elevated associated risk of any psychiatric disorders. In contrast, we found an inverse association for IgG level (HR, 0.92; 95% CI, 0.89-0.94). The estimates were comparable for depression, anxiety, and stress-related disorders, specifically, and these results were largely validated in the UK Biobank (n = 485 620). Analyses of trajectories revealed that individuals with psychiatric disorders had higher levels of leukocytes and haptoglobin and a lower level of IgG than their controls up to 30 years before the diagnosis. The MR analysis suggested a possible causal relationship between leukocytes and depression.

Conclusions and relevance: In this cohort study, inflammatory biomarkers including leukocytes, haptoglobin, CRP, and IgG were associated with a subsequent risk of psychiatric disorders, and thus might be used for high-risk population identification. The possible causal link between leukocytes and depression supports the crucial role of inflammation in the development of psychiatric disorders.

重要性:据报道,精神障碍患者的炎症生物标志物水平升高,而关于炎症生物标志物与后续精神障碍风险之间关系的前瞻性证据却很有限:评估炎症生物标志物与后续精神障碍风险之间的关联:这是一项前瞻性队列研究,研究对象包括瑞典载脂蛋白死亡率风险(AMORIS)队列中既往未被诊断为精神病且至少测量过一种炎症生物标志物的个体。英国生物库的数据用于验证。通过巢式病例对照研究,观察了AMORIS队列中精神病诊断前所研究生物标志物的纵向轨迹。此外,还进行了遗传相关性和亡羊补牢式随机化(MR)分析,利用公开的GWAS汇总统计数据确定研究关联的遗传重叠和因果关系:炎症生物标志物,如白细胞、隐球蛋白、免疫球蛋白 G (IgG)、C 反应蛋白 (CRP)、血小板或白蛋白:任何精神障碍或特定精神障碍(即抑郁症、焦虑症和压力相关障碍)均通过《国际疾病统计分类》第八、第九和第十修订版代码进行识别:在 AMORIS 队列的 585 279 人(平均 [SD] 年龄,45.5 [14.9] 岁;306 784 名男性 [52.4%])中,白细胞水平高于中位数的人(危险比 [HR],1.11;95% CI,1.09-1.14)、高铁血红蛋白(HR,1.13;95% CI,1.12-1.14)或 CRP(HR,1.02;95% CI,1.00-1.04)高于中位数水平的个体罹患任何精神疾病的相关风险都会升高。与此相反,我们发现 IgG 水平(HR,0.92;95% CI,0.89-0.94)与此呈负相关。具体而言,抑郁症、焦虑症和压力相关疾病的估计值相当,这些结果在英国生物库(n = 485 620)中得到了很大程度的验证。轨迹分析表明,与对照组相比,精神障碍患者在确诊前30年内的白细胞和高铁血红蛋白水平较高,IgG水平较低。磁共振分析表明,白细胞与抑郁症之间可能存在因果关系:在这项队列研究中,包括白细胞、高铁血红蛋白、CRP 和 IgG 在内的炎症生物标志物与随后的精神障碍风险有关,因此可用于高危人群的识别。白细胞与抑郁症之间可能存在的因果关系支持了炎症在精神疾病发展中的关键作用。
{"title":"Inflammatory Biomarkers and Risk of Psychiatric Disorders.","authors":"Yu Zeng, Charilaos Chourpiliadis, Niklas Hammar, Christina Seitz, Unnur A Valdimarsdóttir, Fang Fang, Huan Song, Dang Wei","doi":"10.1001/jamapsychiatry.2024.2185","DOIUrl":"10.1001/jamapsychiatry.2024.2185","url":null,"abstract":"<p><strong>Importance: </strong>Individuals with psychiatric disorders have been reported to have elevated levels of inflammatory biomarkers, and prospective evidence is limited regarding the association between inflammatory biomarkers and subsequent psychiatric disorders risk.</p><p><strong>Objective: </strong>To assess the associations between inflammation biomarkers and subsequent psychiatric disorders risk.</p><p><strong>Design, setting, and participants: </strong>This was a prospective cohort study including individuals from the Swedish Apolipoprotein Mortality Risk (AMORIS) cohort, with no prior psychiatric diagnoses and having a measurement of at least 1 inflammatory biomarker. Data from the UK Biobank were used for validation. Longitudinal trajectories of studied biomarkers were visualized before diagnosis of psychiatric disorders in the AMORIS cohort via a nested case-control study. In addition, genetic correlation and mendelian randomization (MR) analyses were conducted to determine the genetic overlap and causality of the studied associations using publicly available GWAS summary statistics.</p><p><strong>Exposures: </strong>Inflammatory biomarkers, eg, leukocytes, haptoglobin, immunoglobulin G (IgG), C-reactive protein (CRP), platelets, or albumin.</p><p><strong>Main outcomes and measures: </strong>Any psychiatric disorder or specific psychiatric disorder (ie, depression, anxiety, and stress-related disorders) was identified through the International Statistical Classification of Diseases, Eighth, Ninth, and Tenth Revision codes.</p><p><strong>Results: </strong>Among the 585 279 individuals (mean [SD] age, 45.5 [14.9] years; 306 784 male [52.4%]) in the AMORIS cohort, individuals with a higher than median level of leukocytes (hazard ratio [HR], 1.11; 95% CI, 1.09-1.14), haptoglobin (HR, 1.13; 95% CI, 1.12-1.14), or CRP (HR, 1.02; 95% CI, 1.00-1.04) had an elevated associated risk of any psychiatric disorders. In contrast, we found an inverse association for IgG level (HR, 0.92; 95% CI, 0.89-0.94). The estimates were comparable for depression, anxiety, and stress-related disorders, specifically, and these results were largely validated in the UK Biobank (n = 485 620). Analyses of trajectories revealed that individuals with psychiatric disorders had higher levels of leukocytes and haptoglobin and a lower level of IgG than their controls up to 30 years before the diagnosis. The MR analysis suggested a possible causal relationship between leukocytes and depression.</p><p><strong>Conclusions and relevance: </strong>In this cohort study, inflammatory biomarkers including leukocytes, haptoglobin, CRP, and IgG were associated with a subsequent risk of psychiatric disorders, and thus might be used for high-risk population identification. The possible causal link between leukocytes and depression supports the crucial role of inflammation in the development of psychiatric disorders.</p>","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"1118-1129"},"PeriodicalIF":22.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11339698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142017592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAMA Psychiatry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1